# The Safety and Efficacy of Lucinactant for Inhalation in Premature Neonates 26 to 32 Weeks Gestational Age

> **NCT02636868** · PHASE2 · COMPLETED · sponsor: **Windtree Therapeutics** · enrollment: 221 (actual)

## Conditions studied

- Respiratory Distress Syndrome

## Interventions

- **DRUG:** Lucinactant delivered via investigational delivery device
- **DRUG:** nCPAP

## Key facts

- **NCT ID:** NCT02636868
- **Lead sponsor:** Windtree Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2017-07
- **Final completion:** 2019-08-06
- **Target enrollment:** 221 (ACTUAL)
- **Last updated:** 2021-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02636868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02636868, "The Safety and Efficacy of Lucinactant for Inhalation in Premature Neonates 26 to 32 Weeks Gestational Age". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02636868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*